Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report


KODAZ H., HACIOĞLU M. B., KÖSTEK O., ERDOĞAN B., TAŞTEKİN E., KODAZ ELPEN Ç., ...Daha Fazla

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.1, sa.1, ss.38-40, 2017 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Vaka Takdimi
  • Cilt numarası: 1 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.14744/ejmo.2017.43153
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Other Indexes
  • Sayfa Sayıları: ss.38-40
  • Anahtar Kelimeler: Adjuvant cisplatin, BRAF, docetaxel, eccrine porocarcinoma, gemcitabine, KRAS, NRAS
  • Marmara Üniversitesi Adresli: Hayır

Özet

Malignant eccrine porocarcinoma is a very rare tumor and the etiology is not known. Treatment is surgical removal of the tumor. The benefit of chemotherapy and radiotherapy is unclear. A 49-year-old male patient presented with the complaint of left inguinal swelling. Ultrasonography examination revealed 5x4 cm inguinal lymphadenopathy. The inguinal lymph nodes were excised. Pathology report indicated eccrine porocarcinoma. The patient was treated with cisplatin 40 mg/m(2) week as well as concurrent radiotherapy for 5 weeks. After 6 weeks of dual therapy, liver metastases were detected. KRAS, NRAS, and BRAF tests were negative. Gemcitabine was administered at a dose of 1000 mg/m(2) on days 1 and 8 every 21 days, and docetaxel was administered at a dose of 75 mg/m(2) on day 8, every 21 days. There was progression after 2 cycles of chemotherapy. The patient lived 7 months. In this case, use of synchronous cisplatin and radiotherapy as adjuvant treatment could not prevent tumor metastasis. The combination chemotherapy of docetaxel and gemcitabine applied after metastatic disease development was ineffective.